20 July 2020: OIA response: hospital purchasing data and Special Authority approvals for azacitidine

20 July 2020 

 

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Thank you for your email of 22 June 2020 requesting information about units of azacitidine purchased by DHBs and Special Authority approvals for azacitidine from 2017 to 2020.  

Your request has been considered pursuant to the Official Information Act 1982 (OIA).

The information you have requested is listed in the table below.

Table 1: Purchased units of Azacitidine in the DHB hospitals for the relevant period

 

Year ending 30 June 2017

Year ending 30 June 2018

Year ended 30 June 2019

Year ended 30 June 2020

Azacitidine 100mg vial (Vidaza)

46.99

154.85

-112.42

0

Azacitidine 100mg vial (Azacitidine Dr Reddy's)

0

0

267.54

242.52

Table 2: Special Authority approvals for initial and renewal applications (SA1467) for Azacitidine for the relevant period

 

Year ending 30 June 2017

Year ending 30 June 2018

Year ended 30 June 2019

Year ended 30 June 2020

Initial approvals (Total)

 93

120 

131

103 

Initial approvals for intermediate-2 or high risk myelodysplastic syndrome

 53

 71

 79

 58

Initial approvals for chronic myelomonocytic leukaemia

 14

 12

 17

 16

Initial Approvals for acute myeloid leukaemia

 25

 34

 24

 21

Renewal approvals

 

 

 

 

Total renewal approvals

 37

 50

 50

 37

Please note that data relating to purchased units of azacytidine is only available up to and including March 2020, therefore the year ended 30 June 2020 is not a complete data set.

Special approval numbers represent distinct patients. The special approval numbers do not necessarily tally, as some initial approvals did not include information about the condition. 

The negative number for Vidaza stock in 2018/19 represents DHBs selling on its stock as the product was delisted. 

We trust that this information answers your queries.  We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this. 

Yours sincerely

 

Rachel Read
Manager, Policy and Government Services